| [29] |
Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I[J]. Clin Pharmacokinet,2009,48(11):689-723.
|
| [30] |
McGraw J, Waller D. Cytochrome P450 variations in different ethnic populations[J]. Expert Opin Drug Metab Toxicol, 2012,8 (3):371-382.
|
| [31] |
Johnson AD,Wang D, Sadee W. Polymorphisms affecting gene regulation and mRNA processing: broad implications for pharmacogenetics[J].Pharmacol Ther,2005,106(1):19-38.
|
| [32] |
Pesenti C,Gusella M,Sirchia SM,et al. Germline oncopharmacogenetics,a promising field in cancer therapy[J]. Cell Oncol (Dordr), 2015,38(1):65-89.
|
| [33] |
Province MA, Goetz MP, Brauch H, et al. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations[J]. Clin Pharmacol Ther,2014,95(2):216-227.
|
| [34] |
Hennig EE, Piatkowska M, Karczmarski J, et al. Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer[J]. BMC Cancer,2015,15:570.
|
| [35] |
Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment[J]. J Natl Cancer Inst,2005,97(1):30-39.
|
| [36] |
Del RM, Citi V, Crucitta S, et al. Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel? [J]. Pharmacol Res,2016,107:398-406.
|
| [37] |
Hertz DL, Deal A, Ibrahim JG, et al. Tamoxifen dose escalation in patients with diminished CYP2D6 activity normalizes endoxifen concentrations without increasing toxicity[J]. Oncologist,2016,21(7):795-803.
|
| [38] |
Dezentjé VO, Opdam FL, Gelderblom H, et al. CYP2D6 genotypeand endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects[J]. Breast Cancer Res Treat,2015,153(3):583-590.
|
| [39] |
Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes[J]. J Clin Oncol,2005,23(36):9312-9318.
|
| [40] |
Goetz MP,Knox SK,Suman VJ,et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen[J]. Breast Cancer Res Treat,2007,101(1):113-121.
|
| [41] |
Schroth W, Antoniadou L, Fritz P, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes[J]. J Clin Oncol,2007,25(33):5187-5193.
|
| [42] |
Bijl MJ, van Schaik RH, Lammers LA, et al. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users[J].Breast Cancer Res Treat,2009,118(1):125-130.
|
| [43] |
Ramóny Cajal T, Altés A, Paré L, et al. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment [J].Breast Cancer Res Treat,2010,119(1):33-38.
|
| [44] |
Newman WG, Hadfield KD, Latif A, et al. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients[J]. Clin Cancer Res,2008,14(18):5913-5918.
|
| [45] |
Xu Y, Sun Y, Yao L, et al. Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment[J]. Ann Oncol,2008,19(8):1423-1429.
|
| [46] |
Lim HS, Ju Lee H, Seok Lee K, et al. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer[J]. J Clin Oncol,2007,25(25):3837-3845.
|
| [47] |
熊萱, 张思超, 朱昶宇.中国人群CYP2D6 的基因多态性与乳腺癌患者他莫昔芬及其代谢物血药浓度关系的Meta 分析[J]. 中国生化药物杂志,2015,35(5):77-80.
|
| [48] |
谢新华, 韦尉东, 孔亚楠,等. 药物代谢酶细胞色素P4502D6 在他莫昔芬个体化治疗中的研究进展[J/CD]. 中华乳腺病杂志(电子版),2011,5(5):601-607.
|
| [49] |
Jung JA, Lim HS. Association between CYP2D6 genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer: a metaanalysis[J]. Pharmacogenomics,2014,15(1):49-60.
|
| [50] |
Sideras K, Ingle JN,Ames MM,et al. Coprescription of tamoxifen and medications that inhibit CYP2D6[J]. J Clin Oncol, 2010,28(16):2768-2776.
|
| [51] |
Rae JM, Drury S, Hayes DF, et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients[J]. J Natl Cancer Inst,2012,104(6):452-460.
|
| [52] |
Goetz MP, Ingle JN. CYP2D6 genotype and tamoxifen: considerations for proper nonprospective studies[J]. Clin Pharmacol Ther, 2014,96(2):141-144.
|
| [53] |
Thompson AM, Johnson A, Quinlan P, et al. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy[J]. Breast Cancer Res Treat, 2011,125(1):279-287.
|
| [54] |
Markkula A, Hjertberg M, Rose C, et al. No association found between CYP2D6 genotype and early breast cancer events in tamoxifentreated patients[J]. Acta Oncol,2014,53(2):195-200.
|
| [55] |
Bauerschlag DO, Maass N, Schem C. Standard of care and controversies in the adjuvant endocrine treatment of hormone-responsive early breast cancer[J]. Breast Care (Basel),2014,9(4):283-286.
|
| [56] |
Kimura M, Tominaga T, Kimijima I, et al. Phase III randomized trial of toremifene versus tamoxifen for Japanese postmenopausal patients with early breast cancer[J]. Breast Cancer,2014,21(3):275-283.
|
| [57] |
Ye QL,Zhai ZM. Toremifene and tamoxifen have similar efficacy in the treatment of patients with breast cancer: a meta-analysis of randomized trials[J]. Mol Biol Rep,2014,41(2):751-756.
|
| [1] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016[J]. CA Cancer J Clin,2016,66(1):7-30.
|
| [2] |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China,2015[J]. CA Cancer J Clin,2016,66(2):115-132.
|
| [3] |
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials[J]. Lancet,2005,365(9472):1687-1717.
|
| [4] |
赵菲.2014 年美国临床肿瘤学会指南更新:激素受体阳性乳腺癌的辅助内分泌治疗[J/CD]. 中华乳腺病杂志(电子版),2014,8(5):373-374.
|
| [5] |
顾军, 于泽平.乳腺癌内分泌治疗的困惑与展望[J/CD]. 中华乳腺病杂志(电子版),2014,8(6):378-383.
|
| [6] |
Jeselsohn R, Buchwalter G, De Angelis C, et al. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer[J]. Nat Rev Clin Oncol,2015,12(10):573-583.
|
| [7] |
杨颖, 胡崇珠. 乳腺癌患者辅助内分泌治疗依从性研究进展[J/CD]. 中华乳腺病杂志(电子版),2014,8(6):48-53.
|
| [8] |
Jordan VC, Allen KE. Evaluation of the antitumour activity of the nonsteroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model[J]. Eur J Cancer,1980,16(2):239-251.
|
| [9] |
Jordan VC. Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer[J]. Endocr Relat Cancer,2014,21(3):R235-246.
|
| [10] |
No authors listed. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation[J]. Lancet, 1983,1(8319):257-261.
|
| [11] |
Fisher B, Redmond C, Wickerham DL, et al. Systemic therapy in patients with node-negative breast cancer. A commentary based on two National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials[J]. Ann Intern Med,1989,111(9):703-712.
|
| [12] |
No authors listed. Tamoxifen for early breast cancer:an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group[J]. Lancet,1998,351(9114):1451-1467.
|
| [13] |
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level metaanalysis of randomised trials[J]. Lancet,2011,378(9793):771-784.
|
| [14] |
Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer:ATLAS,a randomised trial[J]. Lancet,2013,381(9869):805-816.
|
| [15] |
Azim HA, Saadeldeen A. Commentary on “aTTom”: long-term effects of continuing adjuvant tamoxifen to 10 years[J]. Chin Clin Oncol,2014,3(1):7.
|
| [16] |
Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapiesimproving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015[J]. Ann Oncol,2015,26(8):1533-1546.
|
| [17] |
Gradishar WJ, Anderson BO, Balassanian R, et al. Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw,2016,14(3):324-354.
|
| [18] |
Blackburn HL, Ellsworth DL, Shriver CD, et al. Role of cytochrome P450 genes in breast cancer etiology and treatment: effects on estrogen biosynthesis, metabolism, and response to endocrine therapy [J].Cancer Causes Control,2015,26(3):319-332.
|
| [19] |
Wu X, Hawse JR, Subramaniam M, et al. The tamoxifen metabolite,endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells[J]. Cancer Res, 2009,69(5):1722-1727.
|
| [20] |
de Vries Schultink AH, Zwart W, Linn SC, et al. Effects of pharmacogenetics on the pharmacokinetics and pharmacodynamics of tamoxifen[J]. Clin Pharmacokinet,2015,54(8):797-810.
|
| [21] |
Watanabe M, Watanabe N, Maruyama S, et al. Comparative metabolic study between two selective estrogen receptor modulators, toremifene and tamoxifen, in human liver microsomes [ J]. Drug Metab Pharmacokinet,2015,30(5):325-333.
|
| [22] |
Utkarsh D, Loretz C,Li AP. In vitro evaluation of hepatotoxic drugs in human hepatocytes from multiple donors: Identification of P450 activity as a potential risk factor for drug-induced liver injuries[J]. Chem Biol Interact,2016,255:12-22.
|
| [23] |
Regan MM, Leyland-Jones B,Bouzyk M,et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial[J]. J Natl Cancer Inst,2012,104(6):441-451.
|
| [24] |
Okishiro M, Taguchi T, Jin KS, et al. Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis,endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen[J]. Cancer, 2009,115(5):952-961.
|
| [25] |
Maximov PY, McDaniel RE, Fernandes DJ, et al. Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes[J]. Br J Pharmacol, 2014,171(24):5624-5635.
|
| [26] |
Martinez de Dueñas E, Ochoa Aranda E, Blancas Lopez-Barajas I, et al. Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype[J]. Breast, 2014,23(4):400-406.
|
| [27] |
张欢,吴斌.CYP2D6 基因多态性在乳腺癌中的价值[J]. 肿瘤基础与临床,2015,28(2):180-184.
|
| [28] |
Sim SC, Ingelman-Sundberg M. The human cytochrome P450 (CYP)allele nomenclature website: a peer-reviewed database of CYP variants and their associated effects [J]. Hum Genet,2010,4(4):278-281.
|